Hematology, Hospital Ramón y Cajal, Madrid, Spain.
Pathology, Hospital Ramón y Cajal, Madrid, Spain.
J Clin Pathol. 2022 Jun;75(6):383-389. doi: 10.1136/jclinpath-2020-207337. Epub 2021 Mar 15.
Secondary haemophagocytic lymphohistiocytosis (sHLH) is characterised by a hyper activation of immune system that leads to multiorgan failure. It is suggested that excessive immune response in patients with COVID-19 could mimic this syndrome. Some COVID-19 autopsy studies have revealed the presence of haemophagocytosis images in bone marrow, raising the possibility, along with HScore parameters, of sHLH.
Our objective is to ascertain the existence of sHLH in some patients with severe COVID-19.
We report the autopsy histological findings of 16 patients with COVID-19, focusing on the presence of haemophagocytosis in bone marrow, obtained from rib squeeze and integrating these findings with HScore parameters. CD68 immunohistochemical stains were used to highlight histiocytes and haemophagocytic cells. Clinical evolution and laboratory parameters of patients were collected from electronic clinical records.
Eleven patients (68.7%) displayed moderate histiocytic hyperplasia with haemophagocytosis (HHH) in bone marrow, three patients (18.7%) displayed severe HHH and the remainder were mild. All HScore parameters were collected in 10 patients (62.5%). Among the patients in which all parameters were evaluable, eight patients (80%) had an HScore >169. sHLH was not clinically suspected in any case.
Our results support the recommendation of some authors to use the HScore in patients with severe COVID-19 in order to identify those who could benefit from immunosuppressive therapies. The presence of haemophagocytosis in bone marrow tissue, despite not being a specific finding, has proved to be a very useful tool in our study to identify these patients.
继发性噬血细胞性淋巴组织细胞增生症(sHLH)的特征是免疫系统过度激活,导致多器官衰竭。有人认为,COVID-19 患者的过度免疫反应可能会模拟这种综合征。一些 COVID-19 尸检研究显示骨髓中存在噬血细胞现象,这与 HScore 参数一起,增加了 sHLH 的可能性。
我们的目的是确定一些重症 COVID-19 患者是否存在 sHLH。
我们报告了 16 例 COVID-19 患者的尸检组织学发现,重点关注骨髓中噬血细胞的存在,这些发现来自肋骨挤压,并将这些发现与 HScore 参数相结合。使用 CD68 免疫组化染色来突出组织细胞和噬血细胞。从电子病历中收集患者的临床演变和实验室参数。
11 例(68.7%)患者骨髓中表现出中度组织细胞增生伴噬血细胞(HHH),3 例(18.7%)患者表现出重度 HHH,其余为轻度。所有 HScore 参数均在 10 例患者(62.5%)中收集。在所有参数均可评估的患者中,8 例(80%)患者的 HScore >169。在任何情况下均未临床怀疑 sHLH。
我们的结果支持一些作者的建议,即对重症 COVID-19 患者使用 HScore 来识别那些可能受益于免疫抑制治疗的患者。尽管骨髓组织中噬血细胞的存在不是特异性发现,但在我们的研究中,它已被证明是识别这些患者的非常有用的工具。